Robert J. Motzer

Oncology

353 E 68th St
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 404 publications

Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma.

Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma.

Journal: Journal for immunotherapy of cancer

Published: July 17, 2026

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma.

Journal: The New England journal of medicine

Published: July 01, 2026

Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER.

Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER.

Journal: The oncologist

Published: May 11, 2026

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Journal: Journal of the National Cancer Institute

Published: April 13, 2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: March 23, 2026

Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.

Sensitive CAR T cells redefine targetable CD70 expression in solid tumors.

Journal: Science (New York, N.Y.)

Published: February 26, 2026

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 10, 2025

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 14, 2025

Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes.

Journal: JCO oncology practice

Published: October 13, 2025

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Journal: CA: a cancer journal for clinicians

Published: September 15, 2025

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 07, 2025

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.

Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study.

Journal: Urologic oncology

Published: August 21, 2025

Showing 1-12 of 404

Last Updated: 09/26/2026